Status:
COMPLETED
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
Lead Sponsor:
Baxalta now part of Shire
Conditions:
Hemophilia A
Eligibility:
MALE
Up to 6 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter S...
Eligibility Criteria
Inclusion
- Subject must have participated and completed participation in Baxter's clinical study 060101
- Subject or parent/legally authorized representative has provided written informed consent
Exclusion
- Subjects who have withdrawn from Baxter's Clinical Study 060101 prior to the termination of the study
Key Trial Info
Start Date :
December 17 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2006
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00189982
Start Date
December 17 2004
End Date
November 10 2006
Last Update
May 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8